Evidence map›Paper›PMID 39120856›Full record

ArticleCell biochemistry and biophysics2024

Active Targets and Potential Mechanisms of Erhuang Quzhi Formula in Treating NAFLD: Network Analysis and Experimental Assessment.

Peiyan Pan, Weijun Chen, Xi Wu, Cong Li, Yuefeng Gao, Dongmei Qin

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peiyan Pan *Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi, China.
Weijun Chen *Xinjiang Second Medical College, Karamay, China.
Xi Wu *Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Cong LiKey Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi, China.
Yuefeng GaoCollege of Applied Engineering, Henan University of Science and Technology, Sanmenxia, China.
Dongmei QinKey Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, School of Pharmacy, Shihezi University, Shihezi, China. qdm_pha@shzu.edu.cn.

Funding

Science and Technology Research and Development Project of Shihezi University RCZK 2018C12the Major science and technology project of Xinjiang Production and Construction Corps 2020AA005the National Natural Science Foundation of China 82160742
6 · The paper itself

Abstract

The purpose of this research was to investigate the main active components, potential targets of action, and pharmacological mechanisms of Erhuang Quzhi Formula (EHQZF) against NAFLD using network pharmacology, molecular docking, and experimental validation. The main active chemical components of EHQZF and the potential targets for treating NAFLD were extracted and analyzed. The PPI network diagram of "Traditional Chinese Medicine-Active Ingredients-Core Targets" was constructed and the GO, KEGG, and molecular docking analysis were carried out. Identification of components in traditional Chinese medicine compounds was conducted by LC-MS. NAFLD models were established and relevant pathologic indicators and Western blot were analyzed in vivo and ex vivo. Totally 8 herbs attributed to the liver meridian and 20 corresponding targets of NAFLD were obtained from EHQZF. Flavonoids and phenolic acids as the main components of EHQZF treated NAFLD through the MAPK/AKT signaling pathway. Pathway enrichment analysis focused on the MAPK/AKT signaling pathway and apoptosis signaling pathway. Molecular docking showed that Quercetin and Luteolin had stable binding structures with AKT1, STAT3, and other targets. Experiments showed that EHQZF reduced lipid accumulation, regulated changes in adipose tissue, inhibited the MAPK/AKT signaling pathway and exert multiple components, several targets, and multiple pathway interactions to treat NAFLD.

Indexed as

Drugs, Chinese HerbalMolecular Docking SimulationNon-alcoholic Fatty Liver DiseaseAnimalsApoptosisLiverLuteolinMaleMedicine, Chinese TraditionalMiceNetwork PharmacologyProtein Interaction MapsProto-Oncogene Proteins c-aktQuercetinRatsSignal TransductionDrugs, Chinese HerbalLuteolinProto-Oncogene Proteins c-aktQuercetinExperimental assessmentLipid accumulationMAPK/AKTNetwork pharmacologyNon-alcoholic fatty liver disease

Identifiers

PMID39120856

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.